<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2005-622</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-760</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Новые данные о глюкозамине сульфате</article-title><trans-title-group xml:lang="en"><trans-title>New data about glucosamin sulphate</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Arwenfeld</surname><given-names>M</given-names></name><name name-style="western" xml:lang="en"><surname>Arwenfeld</surname><given-names>M</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>15</day><month>08</month><year>2005</year></pub-date><volume>43</volume><issue>4</issue><issue-title>№4 (2005)</issue-title><fpage>76</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Arwenfeld M., 2005</copyright-statement><copyright-year>2005</copyright-year><copyright-holder xml:lang="ru">Arwenfeld M.</copyright-holder><copyright-holder xml:lang="en">Arwenfeld M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/760">https://rsp.mediar-press.net/rsp/article/view/760</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Felson D.T., Zhand Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthr.Reum., 1998,41. 1343-1355&lt;/p&gt;&lt;p&gt;Oliveira S.A., Felson D.T., ReedJ.l. Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintenance organization. Arthr.Reum.,1995, 38. 1134-1141&lt;/p&gt;&lt;p&gt;Pendleton A., Arden N. Dougados M. et al. EULAR recommendations for the management of knee osteoarthritis: report of a task of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rcum.Dis., 2000,59,936-944&lt;/p&gt;&lt;p&gt;Guccione A.A., Felson D.T., Anderson J.J. et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am.J.Public Health, 1994,84, 351-358&lt;/p&gt;&lt;p&gt;Setnikar I., Rovati L.C., Absorplion, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittelforschung, 2001,51, 699-725&lt;/p&gt;&lt;p&gt;Noyszewski E.A., Wroblewski K., Dodge G.R. et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroilin sulfates in articular cartilage explanls. Arthr.Reum., 2001, 44, 1089-1095&lt;/p&gt;&lt;p&gt;Bassleer C., Rovati L.C., Franchimont P. Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthr. Cartil., 1998, 6, 427-434&lt;/p&gt;&lt;p&gt;Piperno М., Reboul P., Helio Le Graverand M.P. et al. Glucosamine sulfate modulates dysregulater activities of human osteoarthritis chondrocytes in vitro. Osteoarthr. Cartil., 2000. 8. 207-212&lt;/p&gt;&lt;p&gt;Dodge G.R., Jimenez SA. Glucosamine sulfate modulates the levels ofaggrecan and matrix meiallopteinase-3 synthesized by cultured humanosteoarthritis articular chondrocytes, Osteoarthr. Cartil., 2003, 11, 424-432&lt;/p&gt;&lt;p&gt;Yaron I., Shirasi I., Judovich R., Yaron M. Glucosamine sulfate inhibits nitric oxide and stromelusin production in carti­lage cultures and reverses IL-1 inhibition of osteoarthritis articular cartilage sintetasis. Ann. Reum.Dis., 2001,60, suppl., 50&lt;/p&gt;&lt;p&gt;Lardo R., Alvares-Soria M.A., Diez-Ortego J. et al. Glucosamine ingibits IL-l(i- induced NF(?B frticulation et al. in human osteoarthritic chondrocytes. Osteoarthr. Cartil., 2003,11, 290-298&lt;/p&gt;&lt;p&gt;Sethikarl. Cereda R., Pacini M.A., Revel L, Antireactive properties of glucosamine sulfate. Arzneimittelforschung, 1991,41,157-161.&lt;/p&gt;&lt;p&gt;Hoffer L.J., Kaplan L.N., Hamadeh M.J. et al. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism, 2001, 50, 767-770.&lt;/p&gt;&lt;p&gt;McAlindon T.E. U Valley M.P., Gulin J.P., Felson D.T. Glucosamine and chondroilin for treatment of osteoarthritis: a ssystematic quality assessment and tneta-analysis. JAMA, 2000, 283, 1469-1475&lt;/p&gt;&lt;p&gt;Egger М., Davey Smith G., Scheneider М., MinderC. Bias in meta analysis detected bi a simple, graphical test. BMJ, 1997,315,629-634&lt;/p&gt;&lt;p&gt;Sterne J.A., Egger М., Smith G.D. Systematic reviews in health care: investigating and dealing with publicacion and other biases in meta analysis. BMJ, 2001., 323, 101-105&lt;/p&gt;&lt;p&gt;Towheend T.E. Anastassiades T.P., Shea B. et al. Glucosamine therapy for treating osteoarthritis (Cochrane Review). ln:The Cochrane Library, Issue 2, 2001. Oxford: Update Software&lt;/p&gt;&lt;p&gt;Lequesne M.G., Mery C., Samson М., Gerard P. Indexes of severity for osteoarthritis of the hip knee. V&amp;amp;lidation-value in comparison with other assessment tests. Scand. J. Reumotol., 1987,65, suppl., 85-89&lt;/p&gt;&lt;p&gt;RichyF., Bruyere O., Ethgen et al. Structural and symptomatic efficacy of glucosamine and chondroilin in knee osteoarthritis. A comprehensive Meta-analysis. Arch, Int. Med., 2003,163,1514-1522&lt;/p&gt;&lt;p&gt;Reginster J.Y., Deroisy R., Rovati L.C. et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo controlled clinical trial. Lancet, 2001,357,251-256&lt;/p&gt;&lt;p&gt;Pavelka K., Gatterova J.OIejarova M. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: 3-year, randomized, placebo-controlled, duble-blind study. Arch. Int. Med.,2002., 162,2113-2123&lt;/p&gt;&lt;p&gt;McAlindon T.E. Glucosamine for osteoarthritis: dawn of a new era? Lancet, 2001,357,247-248&lt;/p&gt;&lt;p&gt;Bruyere O.Honore A., Rovati L.C. et al. Rndililogic features poorly predict clinical outcomes in knee osteoarthritis. Scand. J. Reumotol., 2002,31,13-16&lt;/p&gt;&lt;p&gt;Bruyere 0.,Honore A., Ethgen O. et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year, prospective, placebo-controlled, study evaluating the of glucosamine sulfate. Osteoarthr. Cartil., 2003, 12, 1-5&lt;/p&gt;&lt;p&gt;Pavelka K., Rovati L.C., Gatterova J. et al. Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Osteoarthr. Cartil., 2002, 10 (suppl. A), S 16-17&lt;/p&gt;&lt;p&gt;Baron A.D., Zhu J.S, Zhu J.H. et al. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocacion in skeletal muscle. Implications for glucose toxicity. J. Clin. Invest., 1995,96, 2792-2801&lt;/p&gt;&lt;p&gt;MonauniT., Zenti M.G., Cretti A. et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes, 2000,49,926-935&lt;/p&gt;&lt;p&gt;Pouwels M.J., Jacobs J.R., Span P.N. et al. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J. Clin. Endocrinol. Metab., 2001, 86, 2099-2103.&lt;/p&gt;&lt;p&gt;Rovati L.C., Annefeld М., Giacovelli G. et al. Glucosamine in osteoarthritis. Lancet, 1999,354,1640&lt;/p&gt;&lt;p&gt;Scroggie D.A., Albright A., Harris M. The effect of glu- cosamine-chondroitin supplementation on glycosylated hemoglobin levels in patiens with type2 diabetes mellitus. A placebo- controlled, duble-blinded, randomized clinical trial. Arch.Int.Med., 2003, 163, 1587-1590&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Felson D.T., Zhand Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthr.Reum., 1998,41. 1343-1355&lt;/p&gt;&lt;p&gt;Oliveira S.A., Felson D.T., ReedJ.l. Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintenance organization. Arthr.Reum.,1995, 38. 1134-1141&lt;/p&gt;&lt;p&gt;Pendleton A., Arden N. Dougados M. et al. EULAR recommendations for the management of knee osteoarthritis: report of a task of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rcum.Dis., 2000,59,936-944&lt;/p&gt;&lt;p&gt;Guccione A.A., Felson D.T., Anderson J.J. et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am.J.Public Health, 1994,84, 351-358&lt;/p&gt;&lt;p&gt;Setnikar I., Rovati L.C., Absorplion, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittelforschung, 2001,51, 699-725&lt;/p&gt;&lt;p&gt;Noyszewski E.A., Wroblewski K., Dodge G.R. et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroilin sulfates in articular cartilage explanls. Arthr.Reum., 2001, 44, 1089-1095&lt;/p&gt;&lt;p&gt;Bassleer C., Rovati L.C., Franchimont P. Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthr. Cartil., 1998, 6, 427-434&lt;/p&gt;&lt;p&gt;Piperno М., Reboul P., Helio Le Graverand M.P. et al. Glucosamine sulfate modulates dysregulater activities of human osteoarthritis chondrocytes in vitro. Osteoarthr. Cartil., 2000. 8. 207-212&lt;/p&gt;&lt;p&gt;Dodge G.R., Jimenez SA. Glucosamine sulfate modulates the levels ofaggrecan and matrix meiallopteinase-3 synthesized by cultured humanosteoarthritis articular chondrocytes, Osteoarthr. Cartil., 2003, 11, 424-432&lt;/p&gt;&lt;p&gt;Yaron I., Shirasi I., Judovich R., Yaron M. Glucosamine sulfate inhibits nitric oxide and stromelusin production in carti­lage cultures and reverses IL-1 inhibition of osteoarthritis articular cartilage sintetasis. Ann. Reum.Dis., 2001,60, suppl., 50&lt;/p&gt;&lt;p&gt;Lardo R., Alvares-Soria M.A., Diez-Ortego J. et al. Glucosamine ingibits IL-l(i- induced NF(?B frticulation et al. in human osteoarthritic chondrocytes. Osteoarthr. Cartil., 2003,11, 290-298&lt;/p&gt;&lt;p&gt;Sethikarl. Cereda R., Pacini M.A., Revel L, Antireactive properties of glucosamine sulfate. Arzneimittelforschung, 1991,41,157-161.&lt;/p&gt;&lt;p&gt;Hoffer L.J., Kaplan L.N., Hamadeh M.J. et al. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism, 2001, 50, 767-770.&lt;/p&gt;&lt;p&gt;McAlindon T.E. U Valley M.P., Gulin J.P., Felson D.T. Glucosamine and chondroilin for treatment of osteoarthritis: a ssystematic quality assessment and tneta-analysis. JAMA, 2000, 283, 1469-1475&lt;/p&gt;&lt;p&gt;Egger М., Davey Smith G., Scheneider М., MinderC. Bias in meta analysis detected bi a simple, graphical test. BMJ, 1997,315,629-634&lt;/p&gt;&lt;p&gt;Sterne J.A., Egger М., Smith G.D. Systematic reviews in health care: investigating and dealing with publicacion and other biases in meta analysis. BMJ, 2001., 323, 101-105&lt;/p&gt;&lt;p&gt;Towheend T.E. Anastassiades T.P., Shea B. et al. Glucosamine therapy for treating osteoarthritis (Cochrane Review). ln:The Cochrane Library, Issue 2, 2001. Oxford: Update Software&lt;/p&gt;&lt;p&gt;Lequesne M.G., Mery C., Samson М., Gerard P. Indexes of severity for osteoarthritis of the hip knee. V&amp;amp;lidation-value in comparison with other assessment tests. Scand. J. Reumotol., 1987,65, suppl., 85-89&lt;/p&gt;&lt;p&gt;RichyF., Bruyere O., Ethgen et al. Structural and symptomatic efficacy of glucosamine and chondroilin in knee osteoarthritis. A comprehensive Meta-analysis. Arch, Int. Med., 2003,163,1514-1522&lt;/p&gt;&lt;p&gt;Reginster J.Y., Deroisy R., Rovati L.C. et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo controlled clinical trial. Lancet, 2001,357,251-256&lt;/p&gt;&lt;p&gt;Pavelka K., Gatterova J.OIejarova M. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: 3-year, randomized, placebo-controlled, duble-blind study. Arch. Int. Med.,2002., 162,2113-2123&lt;/p&gt;&lt;p&gt;McAlindon T.E. Glucosamine for osteoarthritis: dawn of a new era? Lancet, 2001,357,247-248&lt;/p&gt;&lt;p&gt;Bruyere O.Honore A., Rovati L.C. et al. Rndililogic features poorly predict clinical outcomes in knee osteoarthritis. Scand. J. Reumotol., 2002,31,13-16&lt;/p&gt;&lt;p&gt;Bruyere 0.,Honore A., Ethgen O. et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year, prospective, placebo-controlled, study evaluating the of glucosamine sulfate. Osteoarthr. Cartil., 2003, 12, 1-5&lt;/p&gt;&lt;p&gt;Pavelka K., Rovati L.C., Gatterova J. et al. Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Osteoarthr. Cartil., 2002, 10 (suppl. A), S 16-17&lt;/p&gt;&lt;p&gt;Baron A.D., Zhu J.S, Zhu J.H. et al. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocacion in skeletal muscle. Implications for glucose toxicity. J. Clin. Invest., 1995,96, 2792-2801&lt;/p&gt;&lt;p&gt;MonauniT., Zenti M.G., Cretti A. et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes, 2000,49,926-935&lt;/p&gt;&lt;p&gt;Pouwels M.J., Jacobs J.R., Span P.N. et al. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J. Clin. Endocrinol. Metab., 2001, 86, 2099-2103.&lt;/p&gt;&lt;p&gt;Rovati L.C., Annefeld М., Giacovelli G. et al. Glucosamine in osteoarthritis. Lancet, 1999,354,1640&lt;/p&gt;&lt;p&gt;Scroggie D.A., Albright A., Harris M. The effect of glu- cosamine-chondroitin supplementation on glycosylated hemoglobin levels in patiens with type2 diabetes mellitus. A placebo- controlled, duble-blinded, randomized clinical trial. Arch.Int.Med., 2003, 163, 1587-1590&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
